within Pharmacolibrary.Drugs.ATC.L;

model L01CE01_1
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.42,
    Cl             = 0.36666666666666664,
    adminDuration  = 600,
    adminMass      = 0.0023,
    adminCount     = 1,
    Vd             = 0.072,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.012666666666666666,
    Tlag           = 13.8
  );

  annotation(Documentation(
    info ="<html><body><p>Topotecan is a topoisomerase I inhibitor used primarily in the treatment of various cancers including ovarian cancer, small cell lung cancer, and cervical cancer. It is an antineoplastic agent that interferes with the replication of DNA in cancer cells. Topotecan is an approved drug and is administered commonly via intravenous infusion or orally.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in adult cancer patients following oral administration.</p><h4>References</h4><ol><li><p>Jeong, SH, et al., &amp; Lee, YB (2021). Oral delivery of topotecan in polymeric nanoparticles: Lymphatic distribution and pharmacokinetics. <i>Journal of controlled release : official journal of the Controlled Release Society</i> 335 86–102. DOI:<a href=&quot;https://doi.org/10.1016/j.jconrel.2021.05.017&quot;>10.1016/j.jconrel.2021.05.017</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34015399/&quot;>https://pubmed.ncbi.nlm.nih.gov/34015399</a></p></li><li><p>Li, N, et al., &amp; Shi, Y (2013). Oral topotecan: Bioavailability, pharmacokinetics and impact of ABCG2 genotyping in Chinese patients with advanced cancers. <i>Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie</i> 67(8) 801–806. DOI:<a href=&quot;https://doi.org/10.1016/j.biopha.2013.08.002&quot;>10.1016/j.biopha.2013.08.002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24074809/&quot;>https://pubmed.ncbi.nlm.nih.gov/24074809</a></p></li><li><p>Herben, VM, et al., &amp; Beijnen, JH (1996). Clinical pharmacokinetics of topotecan. <i>Clinical pharmacokinetics</i> 31(2) 85–102. DOI:<a href=&quot;https://doi.org/10.2165/00003088-199631020-00001&quot;>10.2165/00003088-199631020-00001</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8853931/&quot;>https://pubmed.ncbi.nlm.nih.gov/8853931</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01CE01_1;
